Provided by Tiger Trade Technology Pte. Ltd.

Anavex Life Sciences

2.66
-0.0900-3.27%
Pre-market: 2.680.0200+0.75%08:30 EDT
Volume:433.77K
Turnover:1.15M
Market Cap:246.51M
PE:-18.40
High:2.74
Open:2.71
Low:2.62
Close:2.75
52wk High:10.38
52wk Low:2.26
Shares:92.67M
Float Shares:87.17M
Volume Ratio:0.94
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1446
EPS(LYR):-0.5438
ROE:-12.80%
ROA:-9.70%
PB:2.19
PE(LYR):-4.89

Loading ...

Top News Today: Stocks Mixed as Traders Await U.S.-Iran Updates

Dow Jones
·
May 19

Anavex options imply 6.3% move in share price post-earnings

TIPRANKS
·
May 19

Anavex Life Sciences Announces COO Departure Amid Restructuring

TIPRANKS
·
May 16

Anavex COO Felix Lauscher exits after interim CEO appointment

Reuters
·
May 16

Anavex Life Sciences files Form 3 for Interim CEO Terrie Kellmeyer

Reuters
·
May 15

Anavex delays filing quarterly report for March 31, 2026 quarter

Reuters
·
May 12

Anavex Life Sciences Corp expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
May 09

Anavex Life Sciences names Terrie Kellmeyer interim CEO, succeeding Missling

TIPRANKS
·
May 07

Anavex Life Sciences Names Interim CEO Amid Leadership Shift

TIPRANKS
·
May 06

Anavex names Terrie Kellmeyer interim CEO after Christopher Missling exit

Reuters
·
May 06

Press Release: Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer

Dow Jones
·
May 06

Anavex Life Sciences files Form 3 for director Axel Paeger

Reuters
·
May 02

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere

Reuters
·
Apr 14

Anavex plans pivotal studies of blarcamesine targeting autism-Alzheimer’s shared autophagy dysfunction

Reuters
·
Apr 14

Anavex Life Sciences to present at Needham Virtual Healthcare Conference

Reuters
·
Apr 07

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 31

BRIEF-Anavex Life Sciences Provides Comprehensive Regulatory Update

Reuters
·
Mar 30

Anavex keeps EMA talks after withdrawing EU blarcamesine filing for early Alzheimer’s

Reuters
·
Mar 30

Anavex Life Sciences Corp - Continues Dialogue With European Medicines Agency on Oral Blarcamesine for Early Alzheimer's Disease

THOMSON REUTERS
·
Mar 30

Ema's Chmp: Application for Initial Marketing Authorisation of Blarcamesine Anavex Was Withdrawn.

THOMSON REUTERS
·
Mar 27